Abstract
It has been known for some time that key genetic changes are the principle mechanism of cancer development. These changes lead to abnormalities in the signalling pathways of cells and result in unregulated cell growth, angiogenesis and metastasis.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Drug Interactions
-
ErbB Receptors / antagonists & inhibitors*
-
Humans
-
Imatinib Mesylate
-
Molecular Biology / trends*
-
Neoplasms / drug therapy*
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrimidines / therapeutic use
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
-
Receptors, Vascular Endothelial Growth Factor / physiology
-
Signal Transduction / drug effects*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
ErbB Receptors
-
Receptors, Vascular Endothelial Growth Factor
-
Trastuzumab